Moussa B. H. Youdim
#94,222
Most Influential Person Now
Moussa B. H. Youdim's AcademicInfluence.com Rankings
Moussa B. H. Youdimmedical Degrees
Medical
#1016
World Rank
#1305
Historical Rank
Pharmacology
#71
World Rank
#94
Historical Rank
Moussa B. H. Youdimbiology Degrees
Biology
#4437
World Rank
#6611
Historical Rank
Neuroscience
#470
World Rank
#489
Historical Rank
Download Badge
Medical Biology
Why Is Moussa B. H. Youdim Influential?
(Suggest an Edit or Addition)Moussa B. H. Youdim's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Iron, brain ageing and neurodegenerative disorders (2004) (1599)
- Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains (1989) (1380)
- The therapeutic potential of monoamine oxidase inhibitors (2006) (1140)
- PGC-1α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease (2010) (699)
- Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness (2006) (563)
- Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain (2005) (525)
- Handbook of Neurochemistry and Molecular Neurobiology (2007) (516)
- Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. (2004) (472)
- The relevance of iron in the pathogenesis of Parkinson’s disease (2011) (430)
- Brain iron and ferritin in Parkinson's and Alzheimer's diseases (1990) (428)
- Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases. (2004) (420)
- Involvement of Protein Kinase C Activation and Cell Survival/ Cell Cycle Genes in Green Tea Polyphenol (−)-Epigallocatechin 3-Gallate Neuroprotective Action* (2002) (399)
- Oxidative stress: Free radical production in neural degeneration (1994) (375)
- Neuroprotection and neurorescue against Aβ toxicity and PKC‐dependent release of non‐amyloidogenic soluble precursor protein by green tea polyphenol (‐)‐epigallocatechin‐3‐gallate (2003) (371)
- Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. (2005) (360)
- Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes (2004) (337)
- Mechanism of 6-hydroxydopamine neurotoxicity. (1997) (334)
- Multifunctional Activities of Green Tea Catechins in Neuroprotection (2005) (325)
- MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. (1991) (305)
- IMPLICATIONS OF COMBINED TREATMENT WITH 'MADOPAR' AND L-DEPRENIL IN PARKINSON'S DISEASE A Long-term Study (1977) (292)
- Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures. (2002) (285)
- Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders. (2006) (278)
- Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. (1995) (264)
- Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. (2005) (252)
- Monoamine Oxidase Activity and Monoamine Metabolism in Brains of Parkinsonian Patients Treated with l‐Deprenyl (1986) (247)
- Gene expression analysis in N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R‐apomorphine (2001) (246)
- Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats (2004) (235)
- Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (‐)‐epigallocatechin‐3‐gallate: implications for neurodegenerative diseases (2004) (233)
- Putative biological mechanisms of the effect of iron deficiency on brain biochemistry and behavior. (1989) (230)
- Ironing Iron Out in Parkinson's Disease and Other Neurodegenerative Diseases with Iron Chelators: A Lesson from 6‐Hydroxydopamine and Iron Chelators, Desferal and VK‐28 (2004) (225)
- Brain iron pathways and their relevance to Parkinson's disease. (2001) (225)
- Neuroprotective molecular mechanisms of (−)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties (2009) (222)
- Neuroprotective Strategies in Parkinson’s Disease (2003) (221)
- Dopamine, 6-hydroxydopamine, iron, and dioxygen--their mutual interactions and possible implication in the development of Parkinson's disease. (1996) (221)
- Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. (2002) (219)
- Multiple Forms of Human Brain Mitochondrial Monoamine Oxidase (1970) (218)
- Role of Iron in Neurodegenerative Disorders (2006) (217)
- Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease (1994) (209)
- Simultaneous Manipulation of Multiple Brain Targets by Green Tea Catechins: A Potential Neuroprotective Strategy for Alzheimer and Parkinson Diseases (2008) (203)
- Novel multifunctional neuroprotective iron chelator‐monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition (2005) (201)
- Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (‐)‐epigallocatechin‐3‐gallate: implications for neurodegenerative diseases (2004) (193)
- Neuroprotection via pro‐survival protein kinase C isoforms associated with Bcl‐2 family members (2004) (179)
- The Relevance of Iron in the Pathogenesis of Parkinson's Disease (2004) (178)
- Reduction of iron‐regulated amyloid precursor protein and β‐amyloid peptide by (–)‐epigallocatechin‐3‐gallate in cell cultures: implications for iron chelation in Alzheimer's disease (2006) (174)
- Iron dysregulation in Alzheimer's disease: Multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents (2007) (172)
- Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators. (2013) (167)
- Iron-binding characteristics of neuromelanin of the human substantia nigra. (2003) (167)
- Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives (2005) (165)
- Multiple Forms of Rat Brain Monoamine Oxidase (1969) (163)
- Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG). (2008) (162)
- Oxidative stress: free radical production in neural degeneration. (1994) (157)
- Rasagiline: A novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity (2010) (157)
- Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline (2004) (155)
- Regulation of Bcl‐2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine (2005) (151)
- Gene Expression Profiling of Sporadic Parkinson's Disease Substantia Nigra Pars Compacta Reveals Impairment of Ubiquitin‐Proteasome Subunits, SKP1A, Aldehyde Dehydrogenase, and Chaperone HSC‐70 (2005) (151)
- Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation. (2004) (150)
- The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenil (2005) (150)
- Molecular Basis of Neuroprotective Activities of Rasagiline and the Anti-Alzheimer Drug TV3326 [lpar;N-Propargyl-(3R) Aminoindan-5-YL)-Ethyl Methyl Carbamate] (2001) (149)
- (-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease. (1983) (145)
- Redox imbalance (2004) (140)
- Iron and α-synuclein in the substantia nigra of MPTP-treated mice (2007) (139)
- The Anti‐Parkinson Drug Rasagiline and Its Cholinesterase Inhibitor Derivatives Exert Neuroprotection Unrelated to MAO Inhibition in Cell Culture and in Vivo (2001) (139)
- Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm study (1985) (138)
- Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. (1996) (133)
- Targeting multiple neurodegenerative diseases etiologies with multimodal-acting green tea catechins. (2008) (132)
- New directions in monoamine oxidase A and B selective inhibitors and substrates. (1991) (132)
- Human platelet monoamine oxidase—A useful enzyme in the study of psychiatric disorders? (1982) (131)
- Nutritional iron and dopamine binding sites in the rat brain (1982) (127)
- Prevention and restoration of lactacystin‐induced nigrostriatal dopamine neuron degeneration by novel brain‐permeable iron chelators (2007) (126)
- Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for Alzheimer's therapy. (2009) (126)
- Therapeutic targets and potential of the novel brain‐ permeable multifunctional iron chelator–monoamine oxidase inhibitor drug, M‐30, for the treatment of Alzheimer's disease 1 (2007) (125)
- Brain iron: a lesson from animal models. (1989) (125)
- Understanding Parkinson's disease. (1997) (125)
- CNS Targets for multi-functional drugs in the treatment of Alzheimer’s and Parkinson’s diseases (2005) (123)
- The neurochemical basis of cognitive deficits induced by brain iron deficiency: involvement of dopamine-opiate system. (2000) (123)
- Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. (2012) (123)
- Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson’s disease and other neurodegenerative diseases (2004) (123)
- Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators (2008) (121)
- Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease. (2014) (121)
- Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism (2007) (121)
- Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases (2005) (119)
- Understanding the broad-spectrum neuroprotective action profile of green tea polyphenols in aging and neurodegenerative diseases. (2011) (117)
- An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic Bcl-2 in human dopaminergic SH-SY5Y cells (2002) (116)
- Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax (2004) (114)
- Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease. (1995) (113)
- Neuroprotective and neuritogenic activities of novel multimodal iron‐chelating drugs in motor‐neuron‐like NSC‐34 cells and transgenic mouse model of amyotrophic lateral sclerosis (2009) (112)
- Long-term consequence of early iron-deficiency on dopaminergic neurotransmission in rats (1986) (110)
- Potential sources of increased iron in the substantia nigra of parkinsonian patients. (2006) (108)
- Brain iron deficiency and excess; cognitive impairment and neurodegenration with involvement of striatum and hippocampus (2008) (108)
- Striatal dopa and glucose metabolism in PD patients with freezing of gait (2006) (107)
- A molecular signature in blood identifies early Parkinson’s disease (2012) (107)
- Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl. (1987) (105)
- Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases. (2000) (105)
- Multiple forms of monoamine oxidase: functional significance. (1972) (102)
- Serotonin neurochemistry revisited: A new look at some old axioms (1986) (101)
- Multi Target Neuroprotective and Neurorestorative Anti-Parkinson and Anti-Alzheimer Drugs Ladostigil and M30 Derived from Rasagiline (2013) (101)
- Impaired iron homeostasis in Parkinson's disease. (2000) (101)
- Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron- chelating- antioxidants, M-30 and green tea polyphenol, EGCG. (2007) (101)
- Influence of neuromelanin on oxidative pathways within the human substantia nigra. (2002) (99)
- Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease (2016) (99)
- Does brain 5-HIAA indicate serotonin release or monoamine oxidase activity? (1985) (97)
- The molecular pharmacology of L-deprenyl. (1992) (97)
- Regulation of protein kinase C by the anti‐Parkinson drug, MAO‐B inhibitor, rasagiline and its derivatives, in vivo (2004) (97)
- MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson’s disease: neuroprotective strategies (2000) (97)
- Multifunctional neuroprotective derivatives of rasagiline as anti-alzheimer’s disease drugs (2011) (96)
- L-Deprenil, A Selective Monoamine Oxidase Type B Inhibitor, in the Treatment of Depression: A Double Blind Evaluation (1983) (94)
- Parkinson's disease: a major hypokinetic basal ganglia disorder (1999) (92)
- From Single Target to Multitarget/Network Therapeutics in Alzheimer’s Therapy (2014) (92)
- Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor (2003) (92)
- Neuroprotective Strategies in Parkinson's Disease Using the Models of 6‐Hydroxydopamine and MPTP a (2000) (91)
- Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation. (2010) (91)
- MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders? (2000) (90)
- Induction of Neurotrophic Factors GDNF and BDNF Associated with the Mechanism of Neurorescue Action of Rasagiline and Ladostigil (2007) (90)
- Pharmacology and neuroprotective properties of rasagiline. (1996) (87)
- Non-steroidal Anti-inflammatory Drugs Stimulate Secretion of Non-amyloidogenic Precursor Protein* (2002) (86)
- Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate. (2004) (84)
- Iron in the brain: implications for Parkinson's and Alzheimer's diseases. (1988) (84)
- Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease (2009) (84)
- Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy. (2010) (83)
- Formation of the Neurotransmitter Glycine from the Anticonvulsant Milacemide Is Mediated by Brain Monoamine Oxidase B (1988) (81)
- Iron and ferritin in substantia nigra in Parkinson's disease. (1993) (80)
- The role of iron in senescence of dopaminergic neurons in Parkinson's disease. (1993) (80)
- Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues. (2004) (80)
- Iron deficiency-induced circadian rhythm reversal of dopaminergic-mediated behaviours and thermoregulation in rats. (1981) (80)
- The emergence of designed multiple ligands for neurodegenerative disorders (2011) (79)
- The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders. (1997) (79)
- Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities. (2010) (79)
- Brain iron : neurochemical and behavioural aspects (1988) (78)
- Brain iron and dopamine receptor function. (1983) (78)
- The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline. (2003) (78)
- Pharmacology of rasagiline (N-propargyl-1R-aminoindan). (1999) (77)
- Properties of purified, soluble monoamine oxidase. (1966) (77)
- Selective MAO-A and B inhibitors, radical scavengers and nitric oxide synthase inhibitors in Parkinson's disease. (1994) (77)
- Neurochemical perspectives to the function of monoamine oxidase (1989) (77)
- Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases (2018) (77)
- DJ‐1 deficiency triggers microglia sensitivity to dopamine toward a pro‐inflammatory phenotype that is attenuated by rasagiline (2014) (77)
- A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo‐APP translation and processing (2006) (75)
- Neurodegeneration and Neuroprotection in Parkinson's Disease (1996) (74)
- Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss. (2001) (74)
- A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson’s disease (2004) (74)
- A novel approach of proteomics and transcriptomics to study the mechanism of action of the antioxidant-iron chelator green tea polyphenol (-)-epigallocatechin-3-gallate. (2007) (73)
- The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30. (2006) (73)
- The novel multi-target iron chelating-radical scavenging compound M30 possesses beneficial effects on major hallmarks of Alzheimer's disease. (2012) (73)
- 5-Hydroxytryptamine release in vivo from a cytoplasmic pool: studies on the 5-HT behavioural syndrome in reserpinized rats. (1985) (72)
- Decreased monoamine oxidase activity in liver of iron-deficient rats. (1969) (72)
- Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs. (2003) (72)
- Metallocorroles as cytoprotective agents against oxidative and nitrative stress in cellular models of neurodegeneration (2010) (71)
- Binding preference of p62 towards LC3-ll during dopaminergic neurotoxin-induced impairment of autophagic flux (2011) (70)
- Mechanism of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine and its prevention by desferrioxamine. (1998) (70)
- cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson's disease. (2000) (70)
- Endothelial cells from bovine adrenal medulla develop capillary-like growth patterns in culture. (1985) (70)
- Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. (1985) (69)
- The effect of yohimbine on brain serotonin metabolism, motor behavior and body temperature of the rat. (1971) (68)
- Monoamine oxidase inhibitors: The state of the art (1981) (67)
- Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases (2006) (67)
- Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease. (2014) (66)
- Restoration of Nigrostriatal Dopamine Neurons in Post-MPTP Treatment by the Novel Multifunctional Brain-Permeable Iron Chelator-Monoamine Oxidase Inhibitor Drug, M30 (2009) (65)
- A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease (2003) (65)
- Antidepressant potentiation of 5-hydroxytryptophan by L-deprenil in affective illness. (1980) (65)
- Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A/monoamine oxidase-B inhibitor in animal models of Parkinson's disease and aging (2015) (64)
- The reaction of bovine and rat liver monoamine oxidase with [14C]-clorgyline and [14C]-deprenyl. (1979) (64)
- (‐)Deprenyl in the Treatment of Parkinson's Disease (1982) (63)
- Nuclear translocation of DJ-1 during oxidative stress-induced neuronal cell death. (2012) (62)
- Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline. (2005) (62)
- Selective mao a and b inhibitors: Their mechanism of action and pharmacology (1983) (62)
- Early and Late Gene Changes in MPTP Mice Model of Parkinson's Disease Employing cDNA Microarray (2002) (61)
- Attenuation of MPTP‐induced dopaminergic neurotoxicity by TV3326, a cholinesterase‐monoamine oxidase inhibitor (2003) (61)
- Neuropharmacological and Neurobiochemical Aspects of Iron Deficiency (1990) (60)
- Multiple forms of mitochondrial monoamine oxidase. (1973) (60)
- Molecular mechanisms for neurodegeneration. Synergism between reactive oxygen species, calcium, and excitotoxic amino acids. (1996) (59)
- The Novel Cholinesterase–Monoamine Oxidase Inhibitor and Antioxidant, Ladostigil, Confers Neuroprotection in Neuroblastoma Cells and Aged Rats (2009) (56)
- Promising anti-Alzheimer's dimer bis(7)-tacrine reduces beta-amyloid generation by directly inhibiting BACE-1 activity. (2008) (56)
- Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression (2002) (56)
- 2 – Monoamine oxidase inhibitor antidepressants (1985) (56)
- Iron, melanin and dopamine interaction: relevance to parkinson's disease (1993) (54)
- Manganese corroles prevent intracellular nitration and subsequent death of insulin-producing cells. (2009) (54)
- Distinction between benign and malignant type of parkinson's disease (1979) (53)
- THE EFFECT OF HEAT, INHIBITORS, AND RIBOFLAVIN DEFICIENCY ON MONOAMINE OXIDASE (1965) (52)
- From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease. (2012) (50)
- A Novel Role for Glyceraldehyde-3-Phosphate Dehydrogenase and Monoamine Oxidase B Cascade in Ethanol-Induced Cellular Damage (2010) (49)
- M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease. (2006) (49)
- Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety. (2006) (49)
- Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil (2006) (48)
- Why Do We Need Multifunctional Neuroprotective and Neurorestorative Drugs for Parkinson's and Alzheimer's Diseases as Disease Modifying Agents (2010) (48)
- Oxygen Free Radicals and Neurodegeneration in Parkinson's Disease: A Role for Nitric Oxide a (1994) (48)
- The application of proteomics and genomics to the study of age-related neurodegeneration and neuroprotection. (2006) (48)
- A Sporadic Parkinson Disease Model via Silencing of the Ubiquitin-Proteasome/E3 Ligase Component SKP1A* (2009) (47)
- Regional siderosis: a new challenge for iron chelation therapy (2013) (47)
- Rasagiline: an anti-Parkinson drug with neuroprotective activity (2003) (47)
- Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease? (2007) (46)
- Comparative Neuroprotective Effects of Rasagiline and Aminoindan with Selegiline on Dexamethasone-Induced Brain Cell Apoptosis (2009) (46)
- Regulation of central and peripheral benzodiazepine receptors in progesterone-treated rats (1987) (46)
- Free radical scavengers: chemical concepts and clinical relevance. (1999) (46)
- Low Dosage of Rasagiline and Epigallocatechin Gallate Synergistically Restored the Nigrostriatal Axis in MPTP-Induced Parkinsonism (2010) (46)
- Identification of growth hormone binding protein in rat serum (1990) (45)
- Up-Regulation of Hypoxia-Inducible Factor (HIF)-1α and HIF-Target Genes in Cortical Neurons by the Novel Multifunctional Iron Chelator Anti-Alzheimer Drug, M30 (2010) (45)
- Molecular mechanisms of the neuroprotective/neurorescue action of multi-target green tea polyphenols. (2012) (45)
- The Future of Neuroprotection (1999) (45)
- Modulation of peripheral benzodiazepine binding sites following chronic estradiol treatment. (1986) (45)
- Novel potential neuroprotective agents with both iron chelating and amino acid-based derivatives targeting central nervous system neurons. (2005) (45)
- Multi-target iron-chelators improve memory loss in a rat model of sporadic Alzheimer's disease. (2015) (44)
- Up-regulation of hypoxia-inducible factor (HIF)-1α and HIF-target genes in cortical neurons by the novel multifunctional iron chelator anti-Alzheimer drug, M30. (2010) (44)
- Neuroprotective therapeutic strategies. Comparison of experimental and clinical results. (1995) (44)
- Oxidation and enzyme-activated irreversible inhibition of rat liver monoamine oxidase-B by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). (1986) (43)
- Parkinson’s Disease and Related Disorders (2006) (43)
- Selective acetylcholinesterase inhibitor activated by acetylcholinesterase releases an active chelator with neurorescuing and anti-amyloid activities. (2010) (42)
- Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline (2002) (42)
- Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease. (2002) (41)
- Iron in the Parkinsonian substantia nigra. (1997) (40)
- A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor. (2011) (40)
- Neurotoxicity and neuroprotection in Parkinson's disease. (1992) (40)
- Iron in Central Nervous System Disorders (2001) (40)
- Modulatory Effects of Thyroxine Treatment on Central and Peripheral Benzodiazepine Receptors in the Rat (1986) (39)
- The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease. (1995) (39)
- On the mode of action of L-deprenyl in the human central nervous system (2005) (39)
- Multi-target, Neuroprotective and Neurorestorative M30 Improves Cognitive Impairment and Reduces Alzheimer's-Like Neuropathology and Age-Related Alterations in Mice (2012) (38)
- The Novel Neuropsychotropic Agent Milacemide Is a Specific Enzyme‐Activated Inhibitor of Brain Monoamine Oxidase B (1989) (38)
- Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition (2005) (38)
- New Approaches to Treating Alzheimer’s Disease (2015) (38)
- A Novel iron-chelating derivative of the neuroprotective peptide NAPVSIPQ shows superior antioxidant and antineurodegenerative capabilities. (2008) (37)
- Typical and Atypical Neuroleptics Induce Alteration in Blood‐Brain Barrier and Brain 59FeCl3 Uptake (1994) (37)
- Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease. (2011) (37)
- Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine. (2000) (37)
- Glyceraldehyde-3-Phosphate Dehydrogenase–Monoamine Oxidase B-Mediated Cell Death-Induced by Ethanol is Prevented by Rasagiline and 1-R-Aminoindan (2009) (36)
- Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β‐amyloid in ageing and Alzheimer's disease (2016) (36)
- N-Methyl, N-propynyl-2-phenylethylamine (MPPE), a Selegiline Analog, Attenuates MPTP-induced Dopaminergic Toxicity with Guaranteed Behavioral Safety: Involvement of Inhibitions of Mitochondrial Oxidative Burdens and p53 Gene-elicited Pro-apoptotic Change (2016) (36)
- Iron and neurodegeneration (1996) (36)
- Isolated chromaffin cells from adrenal medulla contain primarily monoamine oxidase B. (1984) (35)
- Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity. (1999) (35)
- The neuroprotective mechanism of action of the multimodal drug ladostigil. (2008) (35)
- What have we learnt from CDNA microarray gene expression studies about the role of iron in MPTP induced neurodegeneration and Parkinson's disease? (2003) (35)
- Multifunctional drugs as neurotherapeutics (2011) (35)
- The neuroprotective effect of ladostigil against hydrogen peroxide-mediated cytotoxicity. (2008) (34)
- The increased opiate action of beta-endorphin in iron-deficient rats: the possible involvement of dopamine. (1984) (34)
- Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax. (2004) (33)
- Proceedings from the "Third International Conference on Mechanism of Action of Nutraceuticals". (2005) (33)
- Selegiline: a molecule with innovative potential (2019) (33)
- The application of proteomics for studying the neurorescue activity of the polyphenol (-)-epigallocatechin-3-gallate. (2008) (33)
- Nutrient deprivation and brain function: iron. (2000) (33)
- The Novel Multifunctional, Iron-Chelating Drugs M30 and HLA20 Protect Pancreatic β-Cell Lines from Oxidative Stress Damage (2010) (33)
- The effect of chronic co-administration of fluvoxamine and haloperidol compared to clozapine on the GABA system in the rat frontal cortex. (2006) (33)
- Gene and protein signatures in sporadic Parkinson's disease and a novel genetic model of PD. (2007) (33)
- Physiological and pathological aspects of Aβ in iron homeostasis via 5'UTR in the APP mRNA and the therapeutic use of iron-chelators (2008) (32)
- Neuroprotection by the multitarget iron chelator M30 on age-related alterations in mice (2012) (32)
- Novel multifunctional anti-Alzheimer drugs with various CNS neurotransmitter targets and neuroprotective moieties. (2007) (32)
- ONTOGENESIS OF ENZYME SYSTEMS DEAMINATING DIFFERENT MONOAMINES (1976) (31)
- The New Inhibitor of Monoamine Oxidase, M30, has a Neuroprotective Effect Against Dexamethasone-Induced Brain Cell Apoptosis (2010) (31)
- Amyloid Processing and Signal Transduction Properties of Antiparkinson‐Antialzheimer Neuroprotective Drugs Rasagiline and TV3326 (2003) (31)
- The effects of iron deficiency and iron and zinc supplementation on rat hippocampus ferritin (2002) (31)
- The novel multi-target iron chelator, M30 modulates HIF-1α-related glycolytic genes and insulin signaling pathway in the frontal cortex of APP/PS1 Alzheimer's disease mice. (2014) (31)
- Neuroprotective and neurorestorative potential of propargylamine derivatives in ageing: focus on mitochondrial targets (2016) (30)
- Increase in central and peripheral benzodiazepine receptors following surgery (1988) (30)
- Activation of monoamine oxidase and inhibition of aldehyde dehydrogenase by reserpine. (1968) (29)
- In the rush for green gold: Can green tea delay age-progressive brain neurodegeneration? (2012) (29)
- The copper chelator, D-penicillamine, does not attenuate MPTP induced dopamine depletion in mice (2007) (29)
- Beef adrenal medulla monoamine oxidase. (1972) (29)
- The novel multitarget iron chelating and propargylamine drug M30 affects APP regulation and processing activities in Alzheimer's disease models (2017) (28)
- Hydrogen peroxide enhances the activity of monoamine oxidase type-B but not of type-A: a pilot study. (1986) (28)
- The cardioprotective efficacy of TVP1022 in a rat model of ischaemia/reperfusion (2011) (28)
- Promise of Neurorestoration and Mitochondrial Biogenesis in Parkinson's Disease with Multi Target Drugs: An Alternative to Stem Cell Therapy (2013) (28)
- Phosphorylation of CHIP at Ser20 by Cdk5 promotes tAIF-mediated neuronal death (2015) (28)
- Monoamine oxidase: multiple forms and selective inhibitors. (1971) (28)
- Promising multifunctional anti-Alzheimer's dimer bis(7)-Cognitin acting as an activator of protein kinase C regulates activities of alpha-secretase and BACE-1 concurrently. (2009) (28)
- The binding of (14C)phenethylhydrazine to rat liver monoamine oxidase. (1975) (27)
- Assay and Purification of Brain Monoamine Oxidase (1975) (27)
- A Novel Iron Chelator-Radical Scavenger Ameliorates Motor Dysfunction and Improves Life Span and Mitochondrial Biogenesis in SOD1G93A ALS Mice (2017) (27)
- Antioxidant properties of the triaminopyridine, flupirtine. (1998) (26)
- Gene expression changes in peripheral mononuclear cells from schizophrenic patients treated with a combination of antipsychotic with fluvoxamine (2007) (26)
- The involvement of BDNF-CREB signaling pathways in the pharmacological mechanism of combined SSRI- antipsychotic treatment in schizophrenia (2017) (26)
- Chronic TVP-1012 (rasagiline) dose--activity response of monoamine oxidases A and B in the brain of the common marmoset. (1998) (26)
- Inhibition of rat liver monoamine oxidase by α-methyl- and N-propargyl-amine derivatives (1982) (26)
- SSRI augmentation of antipsychotic alters expression of GABA(A) receptor and related genes in PMC of schizophrenia patients. (2011) (26)
- Site-Activated Chelators Derived from Anti-Parkinson Drug Rasagiline as a Potential Safer and More Effective Approach to the Treatment of Alzheimer’s Disease (2010) (26)
- Green tea polyphenol (-)-epigallocatechin-3-gallate protects rat PC12 cells from apoptosis induced by serum withdrawal independent of P13-Akt pathway. (2003) (26)
- Multifunctional pharmacotherapy: What can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia? (2011) (26)
- A Novel Antioxidant Multitarget Iron Chelator M30 Protects Hepatocytes against Ethanol-Induced Injury (2015) (25)
- Brain Iron Metabolism Biochemical and Behavioral Aspects Relation to Dopaminergic Neurotransmission (1985) (25)
- Molecular mechanisms underlying synergistic effects of SSRI–antipsychotic augmentation in treatment of negative symptoms in schizophrenia (2009) (25)
- Promotion of 4-Hydroxy-3-methoxy-phenylglycol Formation in Man by Reserpine (1968) (25)
- Early and late molecular events in neurodegeneration and neuroprotection in Parkinson’s disease MPTP model as assessed by cDNA microarray; the role of iron (2002) (25)
- Differential Alterations in Metabolism and Proteolysis-Related Proteins in Human Parkinson’s Disease Substantia Nigra (2018) (25)
- Effect of long-term treatment with rasagiline on cognitive deficits and related molecular cascades in aged mice (2015) (25)
- Function and Regulation of Monoamine Enzymes: Basic and Clinical Aspects (1981) (25)
- Platelet monoamine oxidase B: Use and misuse (1988) (25)
- Anti-inflammatory and protective effects of MT-031, a novel multitarget MAO-A and AChE/BuChE inhibitor in scopolamine mouse model and inflammatory cells (2017) (24)
- Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson’s disease drug, rasagiline compared with selegiline, in the rat midbrain (2009) (24)
- Limited Potentiation of Blood Pressure in Response to Oral Tyramine by the Anti-Parkinson Brain Selective Multifunctional Monoamine Oxidase-AB Inhibitor, M30 (2010) (24)
- The MPTP-Induced Parkinsonian Syndrome in the Goldfish Is Associated with Major Cell Destruction in the Forebrain and Subtle Changes in the Optic Tectum (1996) (24)
- Modulation of dopamine receptor in the striatum by iron: behavioral and biochemical correlates. (1984) (24)
- The dissociation and reassociation of rat liver mitochondrial monoamine oxidase. (1971) (23)
- Binding of oestradiol, progesterone and prolactin in rat lung. (1983) (23)
- Multifunctional neuroprotective drugs for the treatment of cognitive and movement impairment disorders, including Alzheimer's and Parkinson's diseases (2006) (23)
- Synthesis and evaluation of peptidic metal chelators for neuroprotection in neurodegenerative diseases. (2005) (23)
- Strategies for the protection of dopaminergic neurons against neurotoxicity (2009) (22)
- New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline. (1996) (22)
- Brain catalase in the streptozotocin-rat model of sporadic Alzheimer’s disease treated with the iron chelator–monoamine oxidase inhibitor, M30 (2015) (22)
- Design, synthesis and evaluation of novel dual monoamine-cholinesterase inhibitors as potential treatment for Alzheimer’s disease (2016) (22)
- Apomorphine, a dopamine receptor agonist with remarkable antioxidant and cytoprotective properties. (1999) (22)
- A model of MPTP-induced Parkinson's disease in the goldfish (2007) (22)
- Physicochemical properties, development, and regulation of central and peripheral monoamine oxidase activity. (1974) (21)
- Biochemical and pharmacological aspects of depression (1989) (21)
- Recent advances in amyotrophic lateral sclerosis research: perspectives for personalized clinical application (2010) (21)
- TVP1022 and Propargylamine Protect Neonatal Rat Ventricular Myocytes Against Doxorubicin-Induced and Serum Starvation-Induced Cardiotoxicity (2008) (21)
- Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer’s and Parkinson’s diseases (2011) (21)
- Deprenyl does not cause insomnia in parkinsonian patients. (1980) (20)
- Gel-based Protease Proteomics for Identifying the Novel Calpain Substrates in Dopaminergic Neuronal Cell* (2013) (20)
- Is selegiline neuroprotective in Parkinson's disease? (1994) (20)
- M30, a brain permeable multitarget neurorestorative drug in post nigrostriatal dopamine neuron lesion of parkinsonism animal models. (2012) (20)
- The Multi-Target Drug M30 Shows Pro-Cognitive and Anti-Inflammatory Effects in a Rat Model of Alzheimer's Disease. (2015) (20)
- Nigericin-induced Impairment of Autophagic Flux in Neuronal Cells Is Inhibited by Overexpression of Bak* (2012) (20)
- Lithium and oxidative stress lessons from the MPTP model of Parkinson's disease (2012) (20)
- Increased platelet adhesion and aggregation in hypertensive patients: effect of atenolol. (1983) (20)
- Monoamine oxidase A upregulated by chronic intermittent hypoxia activates indoleamine 2,3-dioxygenase and neurodegeneration (2017) (20)
- Aromatic amino acid hydroxylases and mental disease (1979) (19)
- Genes and oxidative stress in parkinsonism: cDNA microarray studies. (2003) (19)
- Effects of novel neuroprotective and neurorestorative multifunctional drugs on iron chelation and glucose metabolism (2012) (19)
- Apomorphine is a potent radical scavenger and protects cultured pheochromocytoma cells from 6-OHDA and H2O2-induced cell death. (1998) (19)
- TVP1022 Protects Neonatal Rat Ventricular Myocytes against Doxorubicin-Induced Functional Derangements (2010) (19)
- Brain monoamine oxidase (MAO) B: A unique neurotoxin and neurotransmitter producing enzyme (1989) (19)
- Lithium’s Gene Expression Profile, Relevance to Neuroprotection A cDNA Microarray Study (2013) (19)
- Inhibition of caspase-9 aggravates acute liver injury through suppression of cytoprotective autophagy (2016) (18)
- Implications of MAO-A and MAO-B inhibition for antidepressant therapy. (1983) (18)
- Inactivation of monoamines by the lung. (1980) (18)
- Degenerative diseases of the nervous system (2007) (18)
- Recent advances in pharmacological therapy of Parkinson's disease. (1993) (17)
- Pharmacological actions of l‐deprenyl (selegiline) and other selective monoamine oxidase B inhibitors * (1994) (17)
- Cellular uptake and organ accumulation of amphipolar metallocorroles with cytoprotective and cytotoxic properties. (2011) (17)
- Beneficial Effects of Multitarget Iron Chelator on Central Nervous System and Gastrocnemius Muscle in SOD1G93A Transgenic ALS Mice (2016) (17)
- Subcellular distribution of steroids in the adrenal gland. (1973) (17)
- Interaction of neuroprotective substances with human brain superoxide dismutase. An in vitro study. (1995) (16)
- Iron-Chelating Drugs Enhance Cone Photoreceptor Survival in a Mouse Model of Retinitis Pigmentosa. (2017) (16)
- MONOAMINE-OXIDASE INHIBITORS AND PROLACTIN SECRETION (1977) (16)
- Preferential release of epinephrine by glycine from adrenal chromaffin cells. (1992) (16)
- Drugs to prevent cell death in Parkinson's disease. Neuroprotection against oxidative stress and inflammatory gene expression. (2001) (16)
- High-affinity strychnine binding to adrenal medulla chromaffin cell membranes. (1990) (16)
- L-deprenyl confers specific protection against MPTP-induced Parkinson's disease-like movement disorder in the goldfish. (1993) (16)
- TVP1022 Attenuates Cardiac Remodeling and Kidney Dysfunction in Experimental Volume Overload-Induced Congestive Heart Failure (2011) (16)
- Polyamines non-competitively inhibit [3H]3-PPP binding to sigma receptors. (1990) (16)
- Deficiency and excess of iron in brain function and dysfunction. (2009) (15)
- From antioxidant chelators to site-activated multi-target chelators targeting hypoxia inducing factor, beta-amyloid, acetylcholinesterase and monoamine oxidase A/B. (2012) (15)
- Modeling sporadic Parkinson's disease by silencing the ubiquitin E3 ligase component, SKP1A. (2009) (15)
- Brain Iron Metabolism (1985) (15)
- Multiple forms of monoamine oxidase. Comparison of in vitro and in vivo inhibition patterns. (1972) (15)
- Multiple forms of monoamine oxidase and their properties. (1972) (14)
- The lung as an endocrine organ. (1983) (14)
- Monoamine oxidase activity during (--)-deprenil therapy: human brain post-mortem studies. (1978) (14)
- Monoamine oxidase B inhibition and the "cheese effect". (1987) (14)
- Binge ethanol exposure increases the Krüppel-like factor 11-monoamine oxidase (MAO) pathway in rats: Examining the use of MAO inhibitors to prevent ethanol-induced brain injury (2016) (14)
- Monoamine oxidase A and B inhibitors in Parkinson's disease. (2007) (13)
- Heterogeneity of Rat Brain and Liver Mitochondrial Monoamine Oxidase: Subcellular Fractionation (1973) (13)
- PC12 cells as a window for the differentiation of neural crest into adrenergic nerve ending and adrenal medulla. (1991) (13)
- The effects of tetrazolium salts on monoamine oxidase activity. (1971) (13)
- The interactions of milacemide with monoamine oxidase. (1994) (12)
- Oxidative stress indices in Parkinson's disease : biochemical determination. (2001) (12)
- The neurotoxic component in Parkinson’s disease may involve iron-melanin interaction and lipid peroxidation in the substantia nigra (1990) (12)
- Additive Neuroprotective Effects of the Multifunctional Iron Chelator M30 with Enriched Diet in a Mouse Model of Amyotrophic Lateral Sclerosis (2016) (12)
- The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine. (1993) (12)
- Social-cooperation differs from individual behavior in hypothalamic and striatal monoamine function: Evidence from a laboratory rat model (2012) (12)
- Novel Therapeutic Approach for Neurodegenerative Pathologies: Multitarget Iron-Chelating Drugs Regulating Hypoxia-Inducible Factor 1 Signal Transduction Pathway (2011) (12)
- The Therapeutic Place and Value of Present and Future MAO-B Inhibitors — l-Deprenyl as the Gold Standard (1993) (12)
- Translocation and oligomerization of Bax is regulated independently by activation of p38 MAPK and caspase-2 during MN9D dopaminergic neurodegeneration (2011) (11)
- The Role of Iron in the Pathogenesis of Parkinson's Disease (2006) (11)
- MAO-A and MAO-B activities in rat striatum, frontal cortex and liver are unaltered after long-term treatment with fluvoxamine and desipramine (2000) (11)
- [72] Assay and purification of liver monoamine oxidase (1987) (11)
- I1 Imidazoline Receptor: Novel Potential Cytoprotective Target of TVP1022, the S-Enantiomer of Rasagiline (2012) (11)
- Impaired autophagic flux is critically involved in drug-induced dopaminergic neuronal death. (2014) (11)
- Anti-depressant potentiation of 5-hydroxytryptophan by L-deprenyl, an MAO “type B” inhibitor (2005) (11)
- Why Do We Need Multifunctional Neuroprotective and Neurorestorative Drugs for Parkinson’s and Alzheimer’s Disorders?** (2010) (11)
- Targeting Skp1, an Ubiquitin E3 Ligase Component Found Decreased in Sporadic Parkinson’s Disease (2011) (11)
- Monoamine oxidase inhibitors as anti-depressant drugs and as adjunct to L-dopa therapy of Parkinson's disease. (1980) (11)
- Heterogeneity of rat brain mitochondrial monoamine oxidase. (1974) (10)
- Experimental iron deficiency in rats: mechanical and electrophysiological alterations in the cardiac muscle. (1996) (10)
- Senile dementia of Alzheimer’s type and Parkinson’s disease: neurochemical overlaps and specific differences (1990) (10)
- Novel chelators targeting cell cycle arrest, acetylcholinesterase, and monoamine oxidase for Alzheimer's therapy. (2012) (10)
- Beneficial behavioral, neurochemical and molecular effects of 1-(R)-aminoindan in aged mice (2015) (10)
- Applying transcriptomic and proteomic knowledge to Parkinson's disease drug discovery (2007) (10)
- Molecular targets of the multifunctional iron‐chelating drug, M30, in the brains of mouse models of type 2 diabetes mellitus (2014) (9)
- Does 1-(R)-aminoindan possess neuroprotective properties against experimental Parkinson's disease? (2011) (9)
- MAO — The Mother of all Amine Oxidases (1998) (9)
- Neurorescue by a ROS Decomposition Catalyst. (2016) (9)
- Proceedings: Influence of endocrine glands on central and peripheral monoamine oxidase activity. (1972) (9)
- The involvement of GABA(A) receptor in the molecular mechanisms of combined selective serotonin reuptake inhibitor-antipsychotic treatment. (2011) (9)
- Regulation of 5-HT catabolism. (1982) (8)
- Improvement in verbal memory following SSRI augmentation of antipsychotic treatment is associated with changes in the expression of mRNA encoding for the GABA-A receptor and BDNF in PMC of schizophrenic patients (2015) (8)
- The Mode of Action of MAO-B Inhibitors (1993) (8)
- Psychiatric, nonmotor aspects of Parkinson's disease. (2012) (8)
- TV3326, A Novel Cholinesterase and Mao Inhibitor (2002) (8)
- Brain iron: function and dysfunction in relation to cognitive processes. (1996) (8)
- The effect of tyramine, reserpine and other drugs on catecholamine metabolism in man. (1968) (8)
- POSTNATAL DEVELOPMENT OF DOPAMINE DEAMINATION IN THE STRIATUM OF THE RAT (1975) (8)
- Enzymes and neurotransmitters in mental disease: Based on a symposium held at the Technion Faculty of Medicine, Haifa, Israel, August 28-30, 1979 (1980) (8)
- Effect of TV 3326 , a novel monoamine-oxidase cholinesterase inhibitor , in rat models of anxiety and depression (8)
- Magic bullets or novel multimodal drugs with various CNS targets for Parkinson's disease? (2007) (7)
- Further properties of multiple forms of mitochondrial monoamine oxidase. (1969) (7)
- Iron and Neurotransmitter Function in the Brain (1997) (7)
- TVP1022: A Novel Cardioprotective Drug Attenuates Left Ventricular Remodeling After Ischemia/Reperfusion in Pigs (2015) (7)
- MAO type B inhibitors as adjunct to L-dopa therapy. (1987) (7)
- Amine Oxidases and Their Impact on Neurobiology (1990) (7)
- The nature of inhibition of cat brain mitochondrial monoamine oxidase by clorgyline (2005) (7)
- Rasagiline in Parkinson's disease. (2010) (7)
- Serotonergic involvement in pharmacological action of the anxiolytic-sedatives thalidomide and supidimide. (1985) (7)
- Deprenyl monotherapy improves visuo-motor control in early parkinsonism. (1998) (7)
- Mechanisms of action of pramipexole: Putative neuroprotective effects (2001) (7)
- A SPORADIC PARKINSON ' S DISEASE MODEL VIA SILENCING OF THE UBIQUITIN-PROTEASOME / E 3-LIGASE COMPONENT , SKP 1 A (2009) (7)
- The effects of iron deficiency and electric shock on learning in rats. (1991) (7)
- Iron-Melanin Interaction in Substantia Nigra as the Neurotoxic Component of Parkinson’s Disease (1990) (6)
- Proceedings: Reduction of platelet monoamine oxidase activity in iron deficiency anaemia. (1974) (6)
- Monoamine Oxidase Type B Inhibitors in Human and Animal Parkinsonism (1986) (6)
- PROPERTIES AND PHYSIOLOGICAL SIGNIFICANCE OF MULTIPLE FORMS OF MITOCHONDRIAL MONOAMINE OXIDASE (MAO) (1975) (6)
- Brain Iron and other Trace Metals in Neurodegenerative Diseases (2000) (6)
- Inhibition of rat liver monoamine oxidase by alpha-methyl- and N-propargyl-amine derivatives. (1982) (6)
- M30 Antagonizes Indoleamine 2,3-Dioxygenase Activation and Neurodegeneration Induced by Corticosterone in the Hippocampus (2016) (6)
- Limitation in the use of tetrazolium salts for the detection of multiple forms of monoamine oxidase. (1972) (6)
- Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease. (1986) (6)
- Genetic reduction of the E3 ubiquitin ligase element, SKP1A and environmental manipulation to emulate cardinal features of Parkinson's disease. (2012) (6)
- Specific changes in type A and B monoamine oxidase activity in different tissues of hypophysectomized rats. (1983) (6)
- The turnover of growth hormone (GH)-binding protein and GH receptor in rabbit and rat (1993) (6)
- Introduction: Examination of clinical and preclinical pharmacologic data relating to abuse liability of l‐deprenyl (selegiline) * (1994) (6)
- Monoamine oxidase type B inhibitors in the treatment of Parkinson's disease. (1984) (5)
- Nanoparticles: a step forward for iron chelation in the brain (2007) (5)
- Microarray expression profiling in 6-hydroxydopamine-induced dopaminergic neuronal cell death (2011) (5)
- Chapter 18:Discovery of Multi-Target Agents for Neurological Diseases via Ligand Design (2012) (5)
- Amine Oxidases: Function and Dysfunction (1994) (5)
- The role of monoamine oxidase A in the metabolism and function of noradrenaline and serotonin (1984) (5)
- The role of GABA-A receptor in the synergism between SSRI and antipsychotic in schizophrenia; implications for antipsychotic modes of actions. (2013) (5)
- Neuroprotection: Past Successes and Future Challenges (2006) (5)
- Enhanced tyramine conjugation in Parkinson's disease. (1974) (5)
- Multiple forms of human brain monoamine oxidase: substrate specificities. (1970) (5)
- A screening system of prodrugs selective for MAO-A or MAO-B. (2004) (5)
- Creation of a gene expression classifier for predicting Parkinson’s disease rate of progression (2020) (5)
- Monoamine oxidases: the present status. (1974) (5)
- Human platelet function as a model for investigating the clinical efficacy of chlorpromazine. (1981) (5)
- Inhibition Patterns of Monoamine Oxidase Isoenzymes: Clinical Implications (1971) (5)
- The role of MAO in dopaminergic transmission. (1990) (5)
- The Essentiality of Iron Chelation in Neuroprotection: A Potential Role of Green Tea Catechins (2005) (4)
- Monoamine metabolism and monoamine oxidase activity in isolated cultured chromaffin cells (1984) (4)
- My love with monoamine oxidase, iron and Parkinson's disease. (2006) (4)
- Normal zinc and iron concentrations in mice after early exposure to phenobarbital (1987) (4)
- The protective, rescue and therapeutic potential of multi-target iron-chelators for retinitis pigmentosa. (2021) (4)
- Proceedings: Substrate and strain-dependent differences in the development of monoamine oxidase in the rat brain. (1975) (4)
- Mechanism of 6-hydroxydopamine induced neurotoxicity of nigra-striatal dopamine neurons (1997) (4)
- Silencing/Overexpressing Selected Genes as a Model of Sporadic Parkinson’s Disease (2010) (4)
- Targeting dysregulation of brain iron homeostasis in ageing (2012) (4)
- Iron, Neuromelanin, and α-Synuclein in Neuropathogenesis of Parkinson's Disease (2003) (4)
- Assay and purification of liver monoamine oxidase. (1987) (4)
- Inhibitors of dopamine inactivating systems as antiparkinson drugs. (1990) (4)
- Monoamine oxidase. Its inhibition. (1975) (4)
- The metabolism of 5-hydroxytryptamine and beta-phenylethylamine in perfused rat lung and in vitro. (1979) (3)
- EFFECT OF HYPOPHYSECTOMY ON TISSUE MAO ACTIVITY (1976) (3)
- Neuromelanin may Mediate Neurotoxicity via its Interaction with Redox Active Iron (2000) (3)
- Serotonin receptor site in human platelets from control and chlorpromazine treated subjects. (1980) (3)
- The implications of increased iron in parkinsonian substantia nigra and its high affinity binding to melanin for dopamine neuron degeneration (1990) (3)
- Antioxidant and Cytoprotective Properties of Apomorphine (1998) (3)
- Genomic aspects of sporadic Parkinson's disease. (2008) (3)
- Potentiation of tyramine pressor responses in conscious rats by reversible inhibitors of monoamine oxidase. (1988) (3)
- Dissociation and reassociation of rat liver mitochondrial monoamine oxidase. (1970) (3)
- Frontiers in Clinical Drug Research - Alzheimer Disorders (2015) (3)
- Multiple forms of monoamine oxidase: some in vivo correlations. (1974) (3)
- Propargylamines Protect Dopamine Cells from Apoptosis Induced by a Neurotoxin, N-Methyl(R) Salsolinol (2000) (3)
- The promotion of phenolic alcohol formation in man by reserpine and ethanol. (1970) (3)
- Chronic treatment with serotonin reuptake inhibitor antidepressant (SSRI) combined with an antipsychotic regulates GABA-A receptor in rat prefrontal cortex (2012) (3)
- Iron deficiency effects on brain function. (2000) (2)
- Iron-Deficiency Anaemia Modifies Brain Function Via Dopamine Receptor Subsensitivity (1984) (2)
- Brain Iron Uptake and Transport in Animal Model of Iron Deficiency, Tardive Dyskinesia and Neurodegenerative Diseases (2001) (2)
- Modulation of peripheral benzodiazepine receptors following chronic estradiol and progesterone treatment (1986) (2)
- Are there MAO inhibitors specific for dopamine metabolism? (1977) (2)
- THE ACTION OF L-DEPRENYL IN L-DOPA TREATED PARKINSONIAN PATIENTS, WITH SPECIAL REFERENCE TO THE ‘ON-OFF’ EFFECT (1980) (2)
- Brain Monoamine Oxidase B Activity and Amino Acid Precursor Treatment of Parkinson’s Disease, Depression and Epilepsy (1988) (2)
- The effect of tyramine on phenolic acid and alcohol excretion in man. (1970) (2)
- Phenylethylamine-oxidizing defect in migraine: circulatory implications. (1975) (2)
- Comparison of the effect of reversible and irreversible MAO inhibitors on renal nerve activity in the anesthetized rat. (1994) (2)
- Multifunctional neuroprotective–neurorescue drugs for Parkinson’s disease (2007) (2)
- Multi-target, Neuroprotective and Neurorestorative M30 Improves Cognitive Impairment and Reduces Alzheimer's-Like Neuropathology and Age-Related Alterations in Mice (2012) (2)
- Dopaminergic neurotransmission and status of brain iron (1989) (2)
- Iron regulation of dopaminergic transmission: relevance to movement disorders (1993) (2)
- Iron Deficiency and Excess in the Brain: Implications for Cognitive Impairment and Neurodegeneration (2009) (2)
- Monoamine oxidase B; a misunderstood and misjudged enzyme. (1988) (2)
- A double-blind placebo study of L-deprenyl in affective disorders (1983) (2)
- Use of Selective Acetylenic MAO Inhibitors in Depression (1981) (2)
- Autoradiographic localization of strychnine-sensitive glycine receptor in bovine adrenal medulla (1993) (2)
- Monoamine oxidases and their inhibitors (2011) (2)
- Neuroprotection and Neuroregeneration in Alzheimer's Disease (2012) (2)
- Determination of the monoamine oxidases (1993) (2)
- Neuroprotective Strategies in Parkinson’s Disease and Huntington’s Chorea (2000) (2)
- Proceedings: Inactivation of phenylethylamine and 5-hydroxytryptamine in rat isolated lungs: evidence for monoamine oxidase A and B in lung. (1975) (2)
- P3.118 Silencing/over-expressing selected genes as a novel model of sporadic Parkinson's disease (2009) (1)
- 2.14.3 NEURORESTORATIVE, NEUROPROTECTIVE AND CELL CYCLE ARREST ACTIVITY OF NOVEL MULTI TARGET DRUGS IN ANIMAL MODELS OF PARKINSON'S DISEASE (2012) (1)
- Rat liver mitochondrial monoamine oxidase, a flavin-containing enzyme. (1971) (1)
- Progress in clinical and biological research. Vol. 90: Beta-carbolines and tetrahydroisoquinolines Edited by Floyd Bloom, Jock Barchas, Merton Sandler and Earl Usdin. Published by Alan R. Liss, New York, 1982. ISBN 0-8451-0090-4 (1983) (1)
- Gene and Protein Expression Profiling in Parkinson's Disease: Quest for Neuroprotective Drugs (2007) (1)
- Brain Iron and Dopamine D2 Receptors in the Rat (1986) (1)
- Oxidant stress effects on nigral cell death: Prospects for neuroprotection (1994) (1)
- Site-activated multi target iron chelators with acetylcholinesterase (AChE) and monoamine oxidase (MAO) inhibitory activities for Alzheimer’s disease therapy (2022) (1)
- Use of a Behavioural Model to Study the Action of Monoamine Oxidase Inhibition in vivo (2008) (1)
- One-Compound-Multi-Targets at Amyloid β Cascade Offered By Bis(7)-Cognitin, a Novel Anti-Alzheimer’s Dimer (2010) (1)
- Neuroprotective Actions of Green Tea Polyphenol, (-)-Epigallocatechin-3-Gallate in Models of Parkinson’s Disease: Gene Targets (2002) (1)
- Proceedings: Multiple forms of MAO: some in vivo correlations. (1974) (1)
- Advances in Research on Neurodegeneration (2000) (1)
- Increase in striatal dopamine following chronic treatment with selective inhibitors of MAO A and B (1995) (1)
- Iron and Parkinson’s Disease (1994) (1)
- Therapeutic potential of a novel multifunctional iron chelator on cognitive decicits and insulin degrading enzyme expression in a rat model of sporadic Alzheimer's disease (2012) (1)
- Therapeutic effects of multifunctional iron-chelating agent in a streptozotocin-induced rat model of sporadic Alzheimer's disease (2013) (1)
- Prevention of dopaminergic toxicity of n methyl 4 phenyl 1 2 5 6 tetrahydropyridine in mice by phenethylamine a specific substrate of type b monoamine oxidase (1985) (1)
- 2250 – THE EFFECT OF TRYPTOLYNES ON PLATELET AGGREGATION AND MONOAMINE METABOLISM (1978) (1)
- A Novel Iron Chelator-Radical Scavenger Ameliorates Motor Dysfunction and Improves Life Span and Mitochondrial Biogenesis in SOD1G93A ALS Mice (2016) (1)
- Lithium’s Gene Expression Profile, Relevance to Neuroprotection A cDNA Microarray Study (2013) (1)
- Green Tea Flavan-3-ols and Their Role in Protecting against Alzheimer’s and Parkinson’s Disease Pathophysiology (2012) (1)
- Proceedings: Physico-chemical properties, development, and regulation of central and peripheral monoamine oxidase activity. (1974) (1)
- Iron dependent mechanisms of dopaminergic toxicity of 6-hydroxydopamine (1996) (1)
- Physiological Aspects of the Oxidative Deamination of Monoamines (2008) (1)
- Beneficial Effects of Multitarget Iron Chelator on Central Nervous System and Gastrocnemius Muscle in SOD1G93A Transgenic ALS Mice (2016) (1)
- Prevention of 1 methyl 4 phenyl 1 2 3 6 tetrahydropyridine induced neurotoxicity by agn 1133 and agn 1135 selective inhibitors of monoamine oxidase b (1985) (1)
- The flavin prosthetic group of purified rat liver mitochondrial monoamine oxidase. (1972) (1)
- Proceedings: Monoamine oxidase active site; the binding to and titration of monoamine oxidase with (14C)-selective inhibitors. (1976) (1)
- Drugs with multiple CNS targets (2004) (1)
- L-dopa and (-)-deprenil in the treatment of Parkinson's disease: a long-term study [proceedings]. (1976) (1)
- Recent Advances in ALS Research: Perspectives for Personalized Clinical Application (2013) (1)
- Questions and Answers (2003) (1)
- From Anti-Parkinson’s Drug Rasagiline to Novel Multitarget Iron Chelators with Acetylcholinesterase and Monoamine Oxidase Inhibitory and Neuroprotective Properties for Alzheimer’s Disease (2020) (1)
- Multifunctional Neuroprotective Drugs for the Treatment of Alzheimer's Disease (2007) (1)
- Novel multi target neuroprotective and neurorestorative drugs for Alzheimer?s Disease (2013) (1)
- Biochemical and Pharmacological Aspects of Depression: Topics in Neurochemistry and Neuropharmacology (1990) (1)
- Propargylamine derivatives provide therapeutic efficacy in in vitro and in vivo experimental models of heart diseases (2006) (0)
- Attenuates Cardiac Remodeling and Kidney Dysfunction in Experimental Volume Overload-Induced Congestive Heart Failure (2011) (0)
- Platelet Adhesion And Aggregation In Behcet’S Syndrome (1981) (0)
- Synergism Between Adrenaline and Adenine Nucleotides in Producing Platelet Aggregation Responses (1979) (0)
- A new selective suicide inhibitor of peripheral DOPA decarboxylase. (1984) (0)
- Phenylethylamine formation in perfused rat liver [proceedings]. (1976) (0)
- Interaction of acetylenic compounds with MAO active site: structure-activity and pharmacological studies (1981) (0)
- 42-1 Therapeutic potentials for reversible MAOA and MAOB inhibitors in the clinic (1997) (0)
- A molecular signature in blood identifies early Parkinson’s disease (2012) (0)
- THE ADVENT OF NEW GENERATION OF MONOAMINE OXIDASE INHIBITOR ANTIDEPRESSANTS (1992) (0)
- Monoamine oxidase inhibitors : the state of the art : based on a symposium of the 12th congress of the collegium internationale neuro-psychopharmacologicum Gothenberg, 22-26 June, 1980 (1981) (0)
- 87 Novel new multi target anti Alzheimer drugs with neuroprotective and neurorestorative activities (2012) (0)
- Neuroprotection and Neurorestoration of Nigra Striatal Dopamine Neurons by Novel Multitarget Drugs, M30 (2021) (0)
- 2.021 Regulation of the iron-responsive proteins amyloid precursor protein and alpha-synuclein by green tea polyphenol (−)-epigallocatechin-3-gallate (2007) (0)
- PL.01.01 Multi-target neuroprotective–neurorestorative drugs for Alzheimer's disease (2011) (0)
- A nucleotide with characteristic platelet aggregation and inhibition properties similar to 5-hydroxytryptamine [proceedings]. (1979) (0)
- Regulation of Functional Cytoplasmic Pool of Serotonin by MAO-A and MAO-B: Implications for Antidepressant Therapy (1989) (0)
- Reversible and selective inhibitors of monoamine oxidase type A : new findings (1995) (0)
- The meeting of minds and times with Peter Riederer: an appreciation (2007) (0)
- Questions and answers: Session VI: Neuroprotective agents and mechanisms (2005) (0)
- 2.317 Regulation of the iron-responsive proteins amyloid precursor protein and alpha-synuclein by green tea polyphenol (−)-epigallocatechin-3-gallate (2007) (0)
- S-51-1 Modulation of cerebral Monoamine release by Mao inhibitors (1996) (0)
- Preface – Special Issue: Neuromelanin (2006) (0)
- Designed multi functional drugs targeting neuroprotection, neurorestoration and mitochondrial biogenesis via activation of HIF1α, SIRT1, PGC-1α and Tfam (2014) (0)
- Discussion: Session 5 — 8 P.M. - 8 February 1993 (1994) (0)
- A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist (2018) (0)
- Supporting Information Site-Activated Chelators Targeting Acetylcholineste rase and Monoamine Oxidase for Alzheimer's Therapy (2010) (0)
- Questions and answers: Session V: Neuroprotective approaches and models (2005) (0)
- Concentration-Dependent Gene and Protein Expressions of Neuroprotective and Neurotoxic Activities of Antioxidants, Including Nutrients (2005) (0)
- Contribution Nuclear translocation of DJ-1 during oxidative stress-induced neuronal cell death (2012) (0)
- Oxygen free radicals and cell death (1992) (0)
- Invitro INHIBITION OFBRAINMITOCHONDRIAL MONOAMINEOXIDASEBY6-HYDROXYDOPAMINE (1975) (0)
- IV.17 Future developments in the treatment of Parkinson's Disease: a case for multifunctional drugs (2006) (0)
- Milacemide: a neuropsychotropic glycine prodrug that potentiates serotonergic activity (1991) (0)
- Subject Index, Vol. 37, 1992 (1992) (0)
- Neurogenic Molecules Modulating Cell Survival Pathways, Amyloid Beta, Tau Proteins, and Metal Dyshomeostasis: An Alternative Hope for Alzheimer’s Therapy (2013) (0)
- Anti-Apoptotic Function of Propargylamines (2002) (0)
- 2.426 Mechanism of degradation of Bad protein by the green tea polyphenol (−)-epigallocatechin-3-gallate: Implication for neuroprotection (2007) (0)
- Session VI: Neuroprotective Agents and Mechanisms (2005) (0)
- Novel Neuroprotective Neurotrophic NAP Analogs Targeting Iron Toxicity and Oxidative Stress in Neurodegenerative Diseases (2006) (0)
- Multimodal neuroprotective–neurorestorative drugs acting on the mitochondria for treatment of Alzheimer's disease (2009) (0)
- Correction: I1 Imidazoline Receptor: Novel Potential Cytoprotective Target of TVP1022, the S-Enantiomer of Rasagiline (2013) (0)
- Session VII: Oxidative Stress, Mitochondria, and Approaches to Neuroprotection (2003) (0)
- Differential Alterations in Metabolism and Proteolysis-Related Proteins in Human Parkinson’s Disease Substantia Nigra (2017) (0)
- PKC and MAP kinase-dependent processing of amyloid precursor protein (APP) by neuroprotective propargylamine cholinesterase inhibitors derived from rasagiline and nonsteroidal anti-inflammatory drugs (2004) (0)
- COMPRISING RON CHELATORS FOR THE TREATMENT OF NEURODEGENERATIVE DSORDERS AND SOME NOVEL RON CHELATORS (2017) (0)
- Appendix I: Assay of Monoamine Oxidase (2008) (0)
- Neuroprotection (2001) (0)
- Environmental factors and movement disorders (2015) (0)
- 2.401 Silencing plus over expression of selected genes as a novel model of sporadic Parkinson's disease (2007) (0)
- Contents, Vol. 40, 1993 (1993) (0)
- Why Multi Target Neuroprotective-Neurorestorative Drugs for Neurodegenerative Diseases (2018) (0)
- c‐DNA Microarray to determine molecular events in neurodegeneration and neuroprotection (2008) (0)
- The In Vitro and In Vivo Molecular Mechanisms of Neuroprotection by the Major Green Tea Polyphenol, (–)-Epigallocatechin-3-gallate, with Special Reference to Parkinson’s Disease (2005) (0)
- Contents of Volumes in the Metal Ions in Life Sciences Series (2019) (0)
- Functional serotonin release occurs from A small, nonvesicular pool (1984) (0)
- 1.011 Early diagnosis for Parkinson's disease according to whole blood gene profile (2007) (0)
- A novel neuroprotective cholinesterase-monoamine oxidase inhibitor for treatment of dementia and depression in Parkinson’s disease (2022) (0)
- Chronic treatment with serotonin reuptake inhibitor antidepressant (SSRI) combined with an antipsychotic regulates GABA-A receptor in rat prefrontal cortex (2011) (0)
- Subject Index, Vol. 40, 1993 (1993) (0)
- Neurotransmitter actions and interactions. Proceedings of a satellite symposium of the 12th International Society for Neurochemistry meeting. Algarve, Portugal, April 29-30, 1989. A tribute to Professor T. L. Sourkes in the year of his 70th birthday. (1990) (0)
- Function and Regulation of Monoamine Enzymes: Basic and Clinical Aspects : Proceedings of a Conference Held at Airlie House, March 6-8, 1981 (1981) (0)
- Contribution of Intracellular Non-Haem Iron, NF-kB Activation and Inflammatory Responses to Neurodegeneration in Parkinson’s Disease: Prospects for Neuroprotection (2000) (0)
- Iron and Monoamine Oxidase in Brain Function and Dysfunction: Development of Neuroprotective-Neurorescue Drugs (2009) (0)
- Correction for the article “Why Do We Need Multifunctional Neuroprotective and Neurorestorative Drugs for Parkinson’s and Alzheimer’s Disorders?” by Moussa B. H. Youdim (2015) (0)
- cDNA microarray to determine early and late gene expression in dopaminergic neurodegeneration (2003) (0)
- Lewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinson’s disease (2023) (0)
- Appendix II: Preparation of Human Platelets (2008) (0)
- Retina Iron-Chelating Drugs Enhance Cone Photoreceptor Survival in a Mouse Model of Retinitis Pigmentosa (2017) (0)
- Structure and function of monoamine enzymes : proceedings of a conference held in Steamboat Springs, Colorado, March 10-13, 1977 (1977) (0)
- Significance of auto regulation of prolactin binding site in the rat lung (1982) (0)
- Long-term Preservation Of Cone Photoreceptors By A Novel Multifunctional Drug In A Mouse Model Of Human Retinitis Pigmentosa (2012) (0)
- S-51-2 Potentials of MAO-A and B inhibitors in the clinic (1996) (0)
- Iron chelators and drug-containing iron chelators for the treatment of neurodegenerative diseases (2000) (0)
- The Molecular Mechanism of the Neuroprotective Action of Antioxidants Compared with the Anti-Parkinson Drug, Rasagiline (2005) (0)
- Title A Novel Antioxidant Multitarget Iron Chelator M 30 ProtectsHepatocytes against Ethanol-Induced Injury (2015) (0)
- Therapeutic potential of a novel multifunctional iron chelator on cognitive decicits and insulin degrading enzyme expression in a rat model of sporadic Alzheimer's disease (2012) (0)
- Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs. (2004) (0)
- Abstracts Second Congress of the European Society for Clinical Neuropharmacology (1995) (0)
- O.090 Modeling sporadic Parkinson's disease by selective gene manipulation (2009) (0)
- A Novel Neuroprotective Cholinesterase and Brain-Selective MAO Inhibitor with APP Processing Activity for the Treatment of Dementia Co-morbid with Depression and Parkinson's Disease (2006) (0)
- Neuroprotection in neurodegeneration (1994) (0)
- Parkinson's disease and milacemide. (1994) (0)
- 248 – EVIDENCE FOR THE PRESENCE OF MONOAMINE OXIDASE “TYPE A” AND “TYPE B” IN PERFUSED RAT LUNG (1977) (0)
- Additive Neuroprotective Effects of the Multifunctional Iron Chelator M30 with Enriched Diet in a Mouse Model of Amyotrophic Lateral Sclerosis (2015) (0)
- Amine oxidases and their impact on neurobiology : proceedings of the 4th International Amine Oxidases Workshop, Würzburg, Federal Republic of Germany, July 7-10, 1990 (1990) (0)
- 1.100 Early diagnosis for Parkinson's disease according to whole blood gene profile (2007) (0)
- Chapter 8 – Genes and Oxidative Stress in Sporadic and Familial Parkinsonism: cDNA Microarray Studies (2007) (0)
- Neurotransmitter Actions and Interactions (1990) (0)
- Questions and answers: Session X: Novel approaches to neuroprotection (2005) (0)
- The clinical and biochemical investigation of L-deprenyl in Parkinson's disease with special reference to the “on-off” effect (1982) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Moussa B. H. Youdim?
Moussa B. H. Youdim is affiliated with the following schools:
